FDA cleared the Endobronchial Blocker Tube (EBT0109); Endobronchial Blocker Tube (EBT0107); Endobronchial Blocker Tube (EBT0105); Endobronchial Blocker Tube (EBT0109S); Endobronchial Blocker Tube (EBT0107S); Endobronchial Blocker Tube (EBT0105S); Endobronchial Blocker Tube (EBT0209); Endobronchial Blocker Tube (EBT0207); Endobronchial Blocker Tube (EBT0205); Endobronchial Blocker Tube (EBT0209S); Endobronchial Blocker Tube (EBT0207S); Endobronchial Blocker Tube (EBT0205S) from Hangzhou Tappa Medical Technology Co., Ltd. on Mar 20, 2026 under K251950, a traditional 510(k). The device falls under product code CBI, Tube, Tracheal/Bronchial, Differential Ventilation (W/Wo Connector), regulated at 21 CFR 868.5740 as a Class 2 device. The review panel was Anesthesiology.

FDA logged the submission as received on Jun 25, 2025. The decision came 268 days later, longer than the 90 FDA-day review goal, which usually means at least one additional information request.

Hangzhou Tappa Medical Technology Co., Ltd. has one other decision in the tracker over the last 12 months: K252861 (Warming System).